Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Masaki, Munakata"'
Autor:
Shohei Igarashi, Norihiro Hanabata, Keisuke Furusawa, Shinya Suto, Miwa Satake, Koji Shimaya, Kosuke Kanazawa, Hiroshi Numao, Masaki Munakata, Hidekachi Kurotaki, Hirotake Sakuraba, Shigeaki Yoshida
Publikováno v:
DEN Open, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract A 37‐year‐old man with systemic lupus erythematosus underwent esophagogastroduodenoscopy as a screening examination for anemia and bloody stool. A semi‐pedunculated edematous lobular polyp of 25 mm in size was detected in the greater c
Externí odkaz:
https://doaj.org/article/60cfc0cc9311454b8480e60f4912b1c7
Autor:
Koichi Shibutani, Norihiro Hanabata, Masaki Munakata, Hiroshi Numao, Kosuke Kanazawa, Keisuke Hasui, Syohei Igarashi, Koji Shimaya, Akihisa Kakuta
Publikováno v:
European journal of gastroenterologyhepatology. 33(11)
Objective Two-dimensional shear wave elastography (2D-SWE) is a new ultrasound-based elastography method to evaluate liver fibrosis in the daily practice. However, the utility of 2D-SWE among the other liver fibrosis markers is unclear. Methods We en
Autor:
Yuh Sakata, Mitsuhiro Kida, Tadanori Yamaguchi, J. Furuse, S. Ohkawa, Taroh Satoh, Atsushi Ishiguro, Norifumi Mizuno, Tatsuya Ioka, Haruo Iguchi, Chikuma Hamada, Mutsukazu Kitano, Masao Tanaka, Masaki Munakata, Takamichi Ito, K. Eguchi, Akihito Tsuji, Kazunori Takeda, Yoshito Komatsu, Takao Itoi
Publikováno v:
British Journal of Cancer
Background: We aimed to compare the efficacy and safety of irinotecan/S-1 (IRIS) therapy with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer. Methods: Patients were treated with oral S-1 (80–120 mg for 14 days every 4 wee
Autor:
Hiroshi Numao, Koji Shimayaa, Akihisa Kakuta, Koichi Shibutani, Syohei Igarashi, Keisuke Hasui, Norihiro Hanabata, Kosuke Kanazawa, Masaki Munakata, Numao, Hiroshi, Shimaya, Koji, Kakuta, Akihisa, Shibutani, Koichi, Igarashi, Syohei, Hasui, Keisuke, Hanabata, Norihiro, Kanazawa, Kosuke, Munakata, Masaki
Publikováno v:
European Journal of Gastroenterology & Hepatology; Nov2021, Vol. 33 Issue 11, p1400-1407, 8p
Autor:
Osamu, Muto, Masaki, Munakata, Kenki, Yamagata, Akio, Masuda, Kei, Kotanagi, Takuya, Kichiraku, Rika, Satoyoshi, Kazuhiro, Kudoh, Toshiya, Sawada, Hideaki, Miyazawa, Shinichiro, Ouchi, Hitoshi, Kotanagi, Yuh, Sakata
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 44(10)
A 32-year-old woman was found to have a gastric adenocarcinoma with multiple bone metastases. Chemotherapy in the first, second and third-line was not effective. Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the s
Autor:
Yoshito Komatsu, Satoshi Yuki, Hiraku Fukushima, Ichiro Iwanaga, Hiroshi Nakatsumi, Yuh Sakata, Mineo Kudo, Yoshimitsu Kobayashi, Takashi Meguro, Takuto Miyagishima, Kazuteru Hatanaka, Susumu Sogabe, Miki Tateyama, Masaki Munakata, Michio Nakamura
Publikováno v:
Acta Oncologica. 51:867-872
Background. In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent col
Autor:
Naoki Ishizuka, Taito Esaki, Yuh Sakata, Yasutsuna Sasaki, Shu Okamura, Yoshihiro Kakeji, Tomohiro Nishina, Yasuhide Yamada, Toshimasa Tsujinaka, Wasaburo Koizumi, Takashi Ura, Masaki Munakata, Taroh Satoh, Ichinosuke Hyodo, Kentaro Yamazaki
Publikováno v:
Cancer Science. 102:1868-1873
Irinotecan-induced severe neutropenia is associated with homozygosity for the UGT1A1*28 or UGT1A1*6 alleles. In this study, we determined the maximum-tolerated dose (MTD) of irinotecan in patients with UGT1A1 polymorphisms. Patients who had received
Publikováno v:
Oncology. 74:135-142
Background: The prognosis of advanced gastrointestinal cancer, especially in patients with poor performance status (PS), is generally dismal. Patients with PS 3–4 are almost ineligible for participation in clinical studies. Patients and Methods: Fr
Autor:
Goetz von Wichert, Dong Wook Shin, Bin Zhou, Hai-Yi Liu, J. Fiore, Giario Conti, Bing Xu, Lie Yang, Sergio Ricci, Kenji Sugamura, Zhengmei Yang, Stefan Breitenstein, Yong Chul Kwon, Davide Radice, Franco Nolè, Sang Yoon Park, Stefan Bierer, Stefan Dold, I. Floriani, Edwin Herrmann, Hidenori Akaike, Yoshiki Mizukami, Yuan Li, M. Medici, Bernhard C. Pestalozzi, Xiao-Gang Shen, Christoph Renner, Bonnie L. Hylander, Koji Kono, Joo-Hyun Nam, C. Marenghi, C. Codecà, F. Gray, M. Polivka, John F. Gibbs, Lothar Hertle, Masaharu Kasai, Quanhai Li, Yu-Fei Jiao, Alan Belicha-Villanueva, Osamu Muto, Laura Adamoli, Kohei Shitara, Chiara Catania, P. Bertheau, J.-M. Molina, Antonio Manganelli, Alessandra Rubagotti, Youquan Bu, D. Ferrari, Peter Kestenholz, Thomas Seufferlein, Elena Verri, Kousaku Mimura, L. Calabrese, Hamdy A. Azim, Chris Andrews, J.-B. Thiebault, Thomas Köpke, Frank Stenner-Liewen, Alberto Lapini, Zong-Guang Zhou, D. Alterio, Panagiotis Samaras, Francesco Boccardo, Noriyuki Yamada, Hidemitsu Sugai, M. Lagrange-Xelot, Julia Braun, Yuh Sakata, P. Foa, Jun-Min Song, Xiao-Feng Sun, Christian Wülfing, Giorgio Cruciani, Sang Min Park, Tamotsu Sugai, Young Ho Yun, Guido Adler, F. Chiesa, Yoshihiko Kawaguchi, Chong Taik Park, Filippo de Braud, Wataru Habano, B. Zuber, Volker Kaechele, Ling Wang, Hideki Fujii, B.A. Jereczek-Fossa, Yu-Jian Zeng, Elizabeth A. Repasky, Michele Battaglia, Fangzhou Song, Hatem A. Azim, Humberto Villavicencio, Aron Goldhirsch, Joachim Gerss, S. Gallien, A. Luciani, Alexander Imhof, Pablo Maroto Rey, Duk-Soo Bae, Jong Min Lee, Rong Wang, Shin-ichi Nakamura, R. Orecchia, Chi-Heum Cho, Tommaso De Pas, Masaki Munakata
Publikováno v:
Oncology. 74:I-IV
Autor:
Satoshi Yuki, Yoshito Komatsu, Yuh Sakata, Osamu Muto, Sen Shimaya, Masaki Munakata, Kohei Shitara
Publikováno v:
Oncology. 75:67-70
Objective: The aim of this study was to evaluate the efficacy and safety of a combination regimen using irinotecan plus S-1 in patients with metastatic pancreatic cancer. Methods: Based on the results of our previous phase I/II study in patients with